Tamsulosin Pregnancy Category
Tamsulosin is FDA Pregnancy Category B 1.
What Category B Means
According to the FDA classification system, Category B indicates that animal reproduction studies have not demonstrated fetal risk, but there are no controlled studies in pregnant women 2. This means:
- Animal studies at doses up to approximately 50 times the human therapeutic exposure showed no evidence of harm to the fetus in rats, and doses up to 50 mg/kg/day in rabbits produced no evidence of fetal harm 1
- However, adequate and well-controlled studies in pregnant women have not been conducted
- Drugs should be given only if potential benefits justify the potential risk to the fetus 2
Clinical Context
It is important to note that tamsulosin is not indicated for use in women 1. The drug is FDA-approved specifically for benign prostatic hyperplasia in men.
Off-Label Use in Pregnancy
Despite the lack of FDA indication for women, tamsulosin has been used off-label as medical expulsive therapy for symptomatic urolithiasis (kidney stones) during pregnancy 3, 4. Research data from this off-label use suggests:
- No significant adverse maternal or fetal outcomes were observed in a retrospective study of 27 pregnant patients 4
- No cases of spontaneous abortion, intrauterine demise, or neonatal congenital anomalies were encountered 4
- All infant birthweights were appropriate for gestational age 4
- However, two randomized controlled studies showed tamsulosin did not significantly improve stone passage rates compared to placebo in pregnant women 3
Important Caveats
The FDA pregnancy category system was discontinued in 2015 and replaced with more detailed pregnancy and lactation labeling. However, tamsulosin retains its historical Category B designation in older references and drug labels still in circulation 1.
Human pregnancy data remains extremely limited, and the Category B classification is based primarily on animal studies rather than human evidence.